Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More
Veronica DeFelice, Director of Biologic Products at Sapio Sciences, looks at how the hit-to-lead process in drug discovery is being impacted by AI and automation. Complexity at the core of hit-to-lead Hit-to-lead (H2L) screening is a critical phase in drug discovery, where researchers narrow down large libraries of compounds, small molecules,… Read More
Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier, looks at how artificial intelligence (AI) can improve the hit-to-lead process for small molecules. Early drug discovery takes an average of three-to-six years and accounts for 42% of total costs1 in the development of a new drug. It’s therefore no surprise that… Read More
This new guide is brought to you by Eurofins Discovery. Download the guide to hit-finding tools that will accelerate your hit to lead and lead optimisation programmes for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity… Read More
Download the guide for hit-finding tools that will accelerate your hit to lead and lead optimisation programs for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity and focused libraries Small molecule and biologics targeted screening for GPCRs, kinases, ion… Read More
